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Abstract
The unfolded protein response (UPR) is an evolutionarily conserved mechanism to allow cells to adapt to stress targeting
the endoplasmic reticulum (ER). Induction of ER chaperone GRP78/BiP increases protein folding capacity; as such it
represents a major survival arm of UPR. Considering the central importance of the UPR in regulating cell survival and death,
evidence is emerging that cells evolve feedback regulatory pathways to modulate the key UPR executors, however, the
precise mechanisms remain to be elucidated. Here, we report the fortuitous discovery of GRP78va, a novel isoform of GRP78
generated by alternative splicing (retention of intron 1) and alternative translation initiation. Bioinformatic and biochemical
analyses revealed that expression of GRP78va is enhanced by ER stress and is notably elevated in human leukemic cells and
leukemia patients. In contrast to the canonical GRP78 which is primarily an ER lumenal protein, GRP78va is devoid of the ER
signaling peptide and is cytosolic. Through specific knockdown of endogenous GRP78va by siRNA without affecting
canonical GRP78, we showed that GRP78va promotes cell survival under ER stress. We further demonstrated that GRP78va
has the ability to regulate PERK signaling and that GRP78va is able to interact with and antagonize PERK inhibitor P58
IPK.
Our study describes the discovery of GRP78va, a novel cytosolic isoform of GRP78/BiP, and the first characterization of the
modulation of UPR signaling via alternative splicing of nuclear pre-mRNA. Our study further reveals a novel survival
mechanism in leukemic cells and other cell types where GRP78va is expressed.
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Introduction
Major advances have been made during the past decade in the
understanding of how cells respond to impairment or saturation of
the protein maturation machinery of the endoplasmic reticulum
(ER). The unfolded protein response (UPR) signaling pathways are
activated to reduce the unfolded protein load and at the same time
increase protein folding capacity. The initiation of UPR is
primarily regulated by the ER-transmembrane sensor proteins
PERK, IRE1 and ATF6 [1,2]. Upon ER stress, PERK activation
leads to phosphorylation of the eukaryotic translation initiation
factor eIF2a, which inhibits global protein biosynthesis while
activating the translation of the transcription factor ATF4. Along
with activated ATF6 and IRE1/XBP-1, ATF4 activates tran-
scription of ER chaperones and folding enzymes, thus improving
the protein processing capacity and alleviating protein aggregation
in the ER.
A major ER chaperone is the 78 kDa glucose regulated protein
GRP78, also referred to as BiP (immunoglobulin heavy chain
binding protein) [3–5]. GRP78 belongs to the HSP70 protein
family and is encoded by a single copy gene in both the human
and mouse genome [6]. In contrast to the cytosolic counterparts of
the HSP70 protein family, the amino-terminus of GRP78 contains
a signal peptide that targets it to the ER and its carboxy-terminus
contains the ER retention signal motif KDEL. The induction of
GRP78 has been widely used as a sentinel marker for ER stress
and UPR activation [7]. As an ER resident protein, GRP78
facilitates protein assembly, prevents intermediates from aggrega-
tion and targets misfolded proteins for degradation [8,9]. In non-
stressed mammalian cells, GRP78 binds to PERK, IRE1 and
ATF6 and maintains them in an inactive form [10,11]. GRP78
also interacts with pro-apoptotic molecules at the ER, blocking
their activation [12–14]. When unfolded proteins pull GRP78
away from them, these pathways are activated, triggering the
UPR, and if the stress is too severe, apoptosis. Therefore, as a key
UPR regulator and target, GRP78 is postulated to play pivotal
roles in pathological processes, however, the precise mechanisms
remain to be determined [15–17].
Considering the central importance of UPR in regulating cell
survival and death [1,2,18,19], the prediction is that cells will evolve
feedback regulatory pathways to modulate the key UPR executors.
One such example is the ER stress induction of the DnaJ family
protein P58
IPK, first discovered as an inhibitor of the eIF2a protein
kinasePKRinthe cytosol [20]. P58
IPKserves asa negativefeedback
of UPR signaling by binding to the cytosolic domain of PERK and
inhibiting its kinase activity, thereby terminating PERK activation
in the late phase of the UPR [21]. As part of a protein complex with
HSP70 at the cytosolic face of translocons, P58
IPK has been
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[22]. Nonetheless, P58
IPK was recently determined to be an ER
lumenal protein, where it acts as a co-chaperone of GRP78 in
protecting the stressed ER [23].
Alternative splicing is increasingly recognized as a crucial
mechanism for generating protein isoforms with distinct cellular
localization and sometimes antagonistic roles regulating survival
and apoptotic processes, impacting various diseases including
cancer [24,25]. We discovered that the human and mouse Grp78
allele contains conserved non-canonical splice sites and ER stress
enhances the production of a variant form of GRP78 through
retention of the first intron and internal translation initiation,
referred to below as GRP78va. Among the various types of
alternative pre-mRNA splicing, intron retention is relatively rare
and few examples of biological consequence are documented [26].
Lacking the ER signal sequence, GRP78va is cytosolic and is
notably elevated in human leukemic cell lines subjected to ER
stress. The transcript of GRP78va is also present in AML, CML
and ALL patients, but not in normal controls. GRP78va is a
promoter of cell survival under ER stress. Through overexpression
and siRNA knockdown studies, we further demonstrated that
GRP78va has the ability to regulate PERK signaling and is able to
interact with and act as an antagonist of PERK inhibitor P58
IPK.
Collectively, these studies provide the first evidence of the
modulation of UPR signaling via alternative splicing of nuclear
pre-mRNA and reveal a fundamentally new concept for a survival
mechanism in leukemic cells and other cell types where GRP78va
is expressed.
Results
Identification of a novel splicing variant of Grp78 in
mouse and human
GRP78 is a highly conserved ER chaperone protein. Critical
domains include the ATPase catalytic domain and the peptide
binding domain (Figure 1A). In both the mouse and human
genome, GRP78 is encoded by a single-copy gene consisting of 8
exons. A novel splicing variant of Grp78 (Grp78va) was discovered
during RT-PCR of Grp78 cDNA prepared from NIH3T3 cells,
using primers spanning the 59 end of exon 1 (p1) and the exon 1/2
junction (p2a) (Figure S1A). To our surprise, two PCR bands were
detected, with the additional upper band clearly evident in cells
treated with the ER stress inducer thapsigargin (Tg) (Figure S1B).
Amplification of genomic DNA was ruled out in control PCR
reactions performed with RNA as template (Figure S1B).
Sequencing of the RT-PCR products revealed that the novel
upper band contains an additional 112 bp intron 1 sequence
which was spliced out in the canonical mouse Grp78 transcript
(Figure S1C). We determined that the fortuitous production of the
novel PCR band could be due to the high sequence homology
between the p2a primer complementary sequence at the exon 1/2
junction and the intron 1/exon 2 junction sequence (Figure S1D),
which led to the amplification of both the canonical Grp78 and the
intron 1 retention variant form. The initial PCR results using
primers p1/p2a were confirmed by using another set of primers
(p1/p2), with p2 flanking the exon 2 of mouse Grp78 (Figure 1A,B).
To further investigate the intron-retention variant form and
determine whether it is expressed beyond cells in culture, two
primer pairs (p1/p3; p4/p5) specific to the Grp78va transcript were
designed, with both p3 and p4 located within intron 1 (Figure 1A).
RT-PCR analysis showed that the Grp78va transcript was detected
in E11.5 mouse embryos and embryonic brain and heart
(Figure 1C). Interestingly, in adult tissues, the Grp78va transcript
was readily detectable in mouse spleen, kidney, liver and
cerebellum, and below detection limit in the heart, intestine, lung
and cerebral cortex (Figure 1D). In every case, expression levels of
Grp78va transcript directly parallel that of the canonical Grp78.
The Grp78va transcript was also detected in a variety of human
monolayer and suspension cell lines, as determined by RT-PCR
using primer pairs p1/p3 and p4/p5 of the human Grp78 sequence
(Figure 2A). As expected, Tg, which depletes the ER Ca
2+ store,
induced the canonical Grp78 transcript, and the levels of Grp78va
transcript were also increased in cells treated with Tg
(Figure 2A,B). In addition, other ER stress inducers, the
glycosylation inhibitor tunicamycin (Tun) and the proline acid
analogue L-azetidine 2-carboxylic acid (AzC), known to induce
canonical Grp78 [3], also induced the expression of Grp78va (Figure
S2). Utilizing quantitative real-time PCR, we further measured
and compared the basal and Tg-induced levels of the Grp78va
transcript (Figure 2B) and the total Grp78 transcript levels in
various human cell lines (Figure 2C). Notably, high basal level of
Grp78va transcript was detected in the human breast cancer cell
line MCF-7 and the human acute promyelocytic leukemia (APL)
cell line HL-60. Among all the cell lines tested, HL-60 also
expressed the highest level of total Grp78 transcripts.
Sequencing of the PCR products shown in Figure 2A confirmed
that the human Grp78va transcript contains the entire 97 bp intron
1 and eight intact exons of human Grp78. The splice donor and
acceptor sites for intron 1 are conserved between mouse and
human (Figure S1C), however, they do not match the optimal
splice site sequences (Figure 1A). The general rules for intron
retention are short intron size (around 100 bp) and suboptimal
splice sites [27]. Interestingly, in addition to intron 1, intron 4 and
5 of the mouse and human Grp78 also fit these criteria, however,
RT-PCR analysis only identified retention for intron 1 and 4
(Table S1).
Elevated Grp78va expression in ER-stressed leukemic cell
lines and leukemia patients
Large-scale microarray using exon-exon junction probes has
been used to monitor alternative splicing events in multi-exon
human genes by comparing the junction probe intensity [28]. The
microarray database deposited in NCBI/GEO contains the
expression data of human Grp78 from each exon-exon junction
probe in 44 human tissue samples and 8 human cancer cell lines.
Comparison of the intensities of exon 1/2 and exon 2/3 junction
probes of Grp78 in 52 samples included in this GEO profile
revealed that the HL-60 and chronic myeloid leukemia (CML)
K562 cell lines have the highest probability to express the intron 1
retention form of Grp78, while adult organs such as the heart,
skeletal muscle and cerebral cortex are the most unlikely (Figure
S3). The microarray analysis prediction that HL-60 and K562
cells express high levels of the Grp78va transcript whereas cerebral
cortex and heart express low levels is in agreement with our
measurements using real-time quantitative PCR (Figure 2B) and
RT-PCR (Figure 1D) of selected human cell lines and mouse
organs.
To further investigate the link between Grp78va and leukemia,
patient bone marrow or peripheral blood samples were collected
from patients diagnosed with AML, CML, ALL and CLL. The
RT-PCR results determining the levels of Grp78va transcript are
summarized in Figure 2D. The Grp78va transcript was expressed at
various levels in AML, CML and ALL patients, but was below
detection limit in normal controls and in CLL patients.
The GRP78va isoform is a cytosolic protein
The translation of canonical GRP78 starts from the AUG
initiation codon located in exon 1 (Figure 1A). However, retention
Cytosolic Form of GRP78/BiP
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the initial AUG. The next potential translation initiation site is an
AUG containing sequence motif in exon 3, which matches the
Kozak sequence (Figure 1A). Translation from this AUG site
maintains the open reading frame of GRP78, generating a
putative GRP78va protein of 507 a.a. (Figure 3A). Compared to
GRP78, GRP78va is predicted to have a truncated amino-
terminus and lack the ER-targeting signal, however, the remainder
of GRP78va isoform will be identical to canonical GRP78 and
recognizable by antibodies against the carboxy-terminus of
GRP78. To test this, the human Grp78va cDNA was subcloned
into the pcDNA3 expression plasmid driven by the CMV/T7
promoter (Figure 3B). This plasmid (pcDNA/Grp78va) was
applied to a coupled in vitro transcription and translation assay to
express GRP78va. A major protein band with a molecular weight
of ,62 kDa was detected (Figure 3C), which is consistent with the
predicted molecular size of GRP78va. Additionally, to achieve
higher expression level of GRP78va, pcDNA/Grp78va-sm was
constructed where the 59 splice donor site of intron 1 was mutated
to inhibit residual splicing of intron 1 (Figure 3B). This mutated
Figure 1. Detection of the alternative splicing transcript Grp78va of mouse Grp78.A .Schematic representation of GRP78 protein domains
and canonical mGrp78 and alternative transcripts. KDEL refers to the ER retention signal. Arrows labeled as p1 to p5 indicate positions of the primers
used in RT-PCR. The sequence of 59 splice site (59ss) and 39 splice site (39ss) of intron 1 are aligned with the optimal splice site sequences. The
translational initiation codon (AUG) and stop codon (UAG) of Grp78 are located in exon 1 and exon 8 respectively. Intron 1 contains a stop codon
UAA. The underlined AUG in exon 3 is a putative initiation site of Grp78va embedded in a consensus Kozak sequence. B. Detection of Grp78va
transcript in mouse NIH3T3 cells by RT-PCR. NIH3T3 cells were either non-treated (2) or treated with 300 nM thapsigargin (Tg) for 16 hours and the
total RNA were subjected to RT-PCR with the indicated primer sets. b-actin levels served as control. C. RT-PCR identification of Grp78va transcript in
E11.5 mouse embryos and indicated organs. D. Detection of Grp78va transcript in adult mouse tissues. Total RNA extracted from the spleen, kidney,
liver, heart, intestine, lung, cerebral cortex and cerebellum of a 5 wk old mouse were subjected to RT-PCR with the indicated primer sets.
doi:10.1371/journal.pone.0006868.g001
Cytosolic Form of GRP78/BiP
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translation assay (Figure 3C), as well as in the transiently
transfected 293T cells (Figure 3D, last lane).
To elucidate the subcellular localization of GRP78va, the
expression plasmid pcDNA/HA-Grp78va was constructed to
allow specific detection of the isoform protein with the HA-tag
antibody (Figure 3B). Confocal immunofluorescence microscopy
showed diffused cytosolic staining for HA-GRP78va, in contrast to
the punctate perinuclear staining for GRP78 typical of ER staining
(Figure 3E). Furthermore, digitonin release experiments were
performed to differentiate the subcellular localization of canonical
GRP78 and GRP78va, with calnexin, a transmembrane ER
protein, serving as control for ER protein and b-actin serving as
control for cytosolic protein. Our results showed that GRP78va
and b-actin were released from the cell after disruption of the
plasma membrane with low concentration (0.01%) of digitonin,
but not canonical GRP78 or calnexin (Figure 3F), confirming that
GRP78va is a cytosolic protein.
To monitor endogenous GRP78va expression in different
human cell lines, post-nuclear (PN) cell lysates were prepared
from HeLa, HCT116 and HL-60 cells to enrich for the cytosolic
isoform GRP78va. Western blot analyses were performed with the
PN fractions from Tg-treated or non-treated cells, with ectopically
expressed GRP78va in 293T cells indicating the size of the isoform
protein (Figure 3D). In all three cell lines, basal GRP78va
expression was detectable, and corresponding with the increase of
Grp78va transcript after Tg stress (Figure 2B), GRP78va protein
level was also increased in the Tg-treated cells (Figure 3D).
Consistent with GRP78va being truncated at the amino-terminus,
antibody against the amino-terminus of GRP78 was unable to
Figure 2. Identification of the Grp78va transcript in human cell lines and leukemia patient samples. A. Expression of the Grp78va
transcript was determined by RT-PCR with the total RNA from the indicated human cell lines, which were either non-treated (2) or treated (+) with Tg
(300 nM) for 16 hours. PCR was performed with specific primers for the human homologue of mGrp78va shown in Figure 1A. B,C. Quantitative real-
time PCR to compare relative expression levels of Grp78va and total Grp78 transcripts in different human cell lines respectively. D. Summary of
Grp78va transcript expression in leukemia patients detected by RT-PCR. RNA samples from the indicated types of leukemia patients were used. b-
actin levels served as control. The patient samples are either from peripheral blood or bone marrow (asterisk). The Grp78 transcript levels after
normalization against b-actin in normal individuals and leukemia patients are shown.
doi:10.1371/journal.pone.0006868.g002
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6868Figure 3. Characterization of human GRP78va protein. A. Schematic diagram comparing the protein domains of canonical GRP78 and
GRP78va. The carboxy-terminal region recognized by the anti-GRP78 monoclonal antibody (Ab) is indicated. B. Schematic diagram of the indicated
GRP78va expression plasmids. The base mutations in the 59 splice site of intron 1 in pcDNA/Grp78va-sm are indicated in red. C. Coupled in vitro
transcription and translation assay to detect the protein products from pcDNA/Grp78va and pcDNA/Grp78va-sm plasmids. D. Detection of
endogenous GRP78va protein in human cell lines. The post-nuclear (PN) fractions from non-treated or Tg-treated HeLa, HCT116 and HL-60 cells were
subjected to Western blot with the anti-GRP78 monoclonal antibody and b-actin served as loading control. GRP78va expression in 293T cells
transfected with pcDNA/Grp78va-sm was used as positive control. A darker exposure of the GRP78va bands is shown below the entire blot. E.
Immunofluorescence staining of GRP78 and GRP78va. HeLa cells were transfected with pcDNA-Grp78 (left panel) or pcDNA/HA-Grp78va (right panel).
The cells were stained with anti-GRP78 antibody (H-129) or anti-HA antibody as indicated, followed by FITC-conjugated secondary antibodies. The
confocal immunofluorescence images are shown. F. Cytosolic localization of GRP78va determined by the cell permeabilization assay. HeLa cells
transiently transfected with pcDNA/HA-GRP78va were treated with 0.01% digitonin for 5 minutes. Intact cells, digitonin-permeabilized cells, and the
released fraction were analyzed by Western blots for the proteins as indicated.
doi:10.1371/journal.pone.0006868.g003
Cytosolic Form of GRP78/BiP
PLoS ONE | www.plosone.org 5 August 2009 | Volume 4 | Issue 8 | e6868detect GRP78va (Figure S4). Further, to rule out the possibility
that GRP78va is a degraded form of GRP78, a siRNA targeting a
21-nucleotide sequence unique to the retained intron 1 of human
Grp78va was utilized to specifically knock down the Grp78va
transcript (Figure S5A). In cells transfected with siGrp78va, the
level of canonical GRP78 was unchanged at both mRNA and
protein levels whereas the level of GRP78va was substantially
reduced at both mRNA and protein levels (Figure S5B-D). This,
coupled with the different cellular localization for GRP78va and
GRP78, indicates that GRP78va is a product of the Grp78va
transcript and not a degraded form of GRP78.
GRP78va specifically enhances PERK signaling in the
unfolded protein response
Canonical GRP78 is known to interact and regulate the
activation of the three major UPR pathways: PERK, IRE1 and
ATF6. As a first step to determine the biological function of
GRP78va, HeLa cell lines stably transfected with pcDNA/HA-
Grp78va or the empty vector were established. Western blot
results showed that stable overexpression of GRP78va did not
significantly affect the basal level or Tg-induction of canonical
GRP78 (Figure 4A). The same cell lysates were analyzed for the
status of the UPR pathways. As shown in Figure 4B, overexpres-
sion of GRP78va strongly activated the ER eIF2a kinase, PERK,
as evidenced by increased phosphorylation of PERK, even in the
absence of ER stress (time 0). Following Tg treatment, PERK
activation was sustained longer than in control cells transfected
with the empty vector. This correlates with enhanced and
sustained eIF2a phosphorylation and higher level of ATF4 upon
Tg treatment (Figure 4B). In contrast, we did not observe any
significant change in ATF6 activation, as measured by proteolytic
cleavage, which may explain why Tg induction of CHOP, co-
regulated by ATF6 and ATF4, was not enhanced in the GRP78va
overexpressed cells (Figure 4C). ER stress activates the kinase and
ribonuclease activities of IRE1, which removes a 26-nucleotide
intron from Xbp1 mRNA (Xbp1-u), giving rise to a spliced mRNA
(Xbp1-s). While the kinetics of Xbp1 splicing was similar in
GRP78va overexpressed and control cells, the ratio of spliced
versus unspliced Xbp1 was slightly lower at 2 to 6 hours in
GRP78va overexpressed cells than in control cells (Figure 4D).
The ATP binding domain of GRP78 is critical for its catalytic
activity, and a single amino acid substitution G227D produced an
ATP binding mutant [29]. Stable HeLa cell lines were established
with this corresponding mutation in GRP78va (G80D) and the
expression level of the mutant form was assayed in parallel with
canonical GRP78va by Western blot (Figure 5A,B). Despite a
slightly higher expression level of the mutant, it did not lead to
enhanced eIF2a phosphorylation in non-stressed (time 0) or Tg-
treated cells as was observed in the GRP78va overexpressed cells
(Figure 5C). These results establish that the ATP binding activity
of GRP78va is essential for its positive regulatory function and
further excludes the possibility that GRP78va overexpression
fortuitously triggered PERK signaling as a consequence of ectopic
protein expression.
To investigate further the relationship between endogenous
GRP78va and PERK activation, we first monitored in HL-60 cells
the kinetics of Tg-induced expression of GRP78va and phosho-
eIF2a as a monitor for PERK activation. GRP78 and total eIF2a
levels were also measured in parallel. Representative gels/blots
and a summary of quantified results from multiple experiments are
shown. The upregulation of GRP78va started at an early stage
(,2 hours) following Tg treatment, at both the mRNA (Figure 5D)
and protein levels (Figure 5E) and the increase was sustained for
16 hours. Interestingly, P58
IPK, a known inhibitor of PERK, was
also quickly induced (from 2 hours) during the same treatment
(Figure 5E), which is different from the previous observation that
P58
IPK is induced at late phase (12 hours) of tunicamycin-induced
ER stress in NIH3T3 cells [30]. Elevation of eIF2a phosphory-
lation was evident within the first hour and sustained throughout
the treatment period (Figure 5E).
GRP78va interacts with P58
IPK and reduces its protein
level
P58
IPK is an inhibitor of PERK acting through the cytosolic
kinase domain of PERK and knockdown of P58
IPK constitutively
activates PERK[21]. SinceGRP78vaactivates PERK signaling,we
tested whether GRP78va diminishes the P58
IPK inhibitory effect on
PERK through protein-protein interaction. Co-immunoprecipita-
tion was performed with lysates from 293T cells co-transfected with
HA-GRP78va and P58
IPK-FLAG, where the FLAG-tag was fused
to the ORF of P58
IPK at the carboxy-terminus, so that it does not
interfere with the amino-terminal ER signal peptide (Figure 6A).
GRP78va was co-immunoprecipitated with P58
IPK in both non-
stressed and Tg-treated cells. Co-immunoprecipitation of GRP78va
was also observed with FLAG-P58
IPK where the FLAG-tag was
fused to the amino-terminus of P58
IPK (Figure 6B). Furthermore,
the interaction between P58
IPK and GRP78va requires the ATP
binding function of GRP78va as the binding of the ATP binding
mutant GRP78va-G80D to P58
IPK was much weaker compared to
wild-type GRP78va (Figure 6B).
Since GRP78va is a cytosolic protein, its interaction with
P58
IPK is expected to occur in the cytosolic compartment. While
originally discovered as a cytosolic protein [20,30], recent evidence
suggests that most P58
IPK is located in the ER lumen as a co-
chaperone of ER lumenal GRP78 [23,31], however its weak signal
sequence allows for inefficient translocation and may therefore
generate some cytosolic forms [23]. Through confocal microscopy
using PDI staining as an ER marker, we observed that while
P58
IPK-FLAG co-localized with PDI in the ER, it was also
detected in the cytosol (Figure S6). The existence of a cytosolic
pool of P58
IPK was further confirmed by digitonin release
experiment, with the heat shock protein HSP70 serving as control
for cytosolic protein and calnexin serving as control for ER
protein. In HeLa cells transfected with P58
IPK-FLAG, we
observed that P58
IPK and HSP70, but not calnexin, was detected
in the released fraction when the cells were treated with low
concentration (0.01%) of digitonin (Figure 6C). Additionally, the
electrophoretic mobility of the released form of P58
IPK was slower
than the form that was retained inside the permeabilized cells,
consistent with previous reports that P58
IPK bearing the signal
peptide migrated slower than the ER form in SDS gel [23,31] and
the weak P58
IPK signal sequence allows for inefficient transloca-
tion into the ER [23]. Thus, both imaging and biochemical studies
suggest that a subfraction of P58
IPK can exist in the cytosolic
compartment.
Next we examined whether there is functional interaction
between GRP78va and P58
IPK. In HeLa cells stably expressing
GRP78va, the level of phospho-eIF2a level was increased by 5.6-
fold compared to vector control; however, upon co-expression
with P58
IPK, this level was reduced to 1.9-fold; whereas
overexpression of P58
IPK alone had no effect on phospho-eIF2a
level (Figure 6D). This implies that P58
IPK is an antagonist of
GRP78va. Conversely, GRP78va is an antagonist of P58
IPK since
stable overexpression of GRP78va in HeLa cells decreased
endogenous P58
IPK by 70% (Figure 6E). Further, modulation of
endogenous P58
IPK by endogenous GRP78va in Tg treated cells
was demonstrated by a 2.8-fold increase in P58
IPK level where
GRP78va was down-regulated by siRNA (Figure 6F).
Cytosolic Form of GRP78/BiP
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induced cell death
Translational attenuation mediated by eIF2a phosphorylation is
a major pro-survival mechanism for the UPR and promotes tumor
cell adaptation to stress [32,33]. Given that leukemia is a highly
malignant disease, GRP78va expression in leukemic cells may
regulate PERK signaling and offer protection against ER stress-
induced apoptosis, leading to survival. To test this, HL-60 cells were
transfected with siGrp78va or control siRNA, and specific
knockdown of GRP78va at the transcript (Figure 7A) and protein
Figure 4. GRP78va enhances PERK signaling. A. Western blots to confirm the ectopical expression of GRP78va. HeLa cells stably transfected
with vector or pcDNA/HA-Grp78va were treated with Tg (300 nM) for the indicated time. HA-GRP78va and endogenous GRP78 were detected by anti-
HA and anti-GRP78 antibody respectively. b-actin levels served as loading control. B. Western blots were performed to detect the kinetics and
magnitude of UPR signaling markers identified on the right following Tg treatment for the indicated time points. The experiments were repeated
twice. The representative results are shown with the ratio (p/t) of p-PERK/PERK or p-eIF2a/eIF2a indicated under each panel with the non-treated
control cells set as 1.0. C. Detection of the CHOP activation and ATF6 cleavage following Tg treatment for the indicated time points. The uncleaved
(p90) and cleaved (p50) forms of ATF6 are indicated. b-actin levels served as loading control. D. RT-PCR to detect Xbp1 splicing following Tg
treatment for the indicated time. The positions of the Xbp1 unspliced (u) and spliced (s) forms were indicated and the ratio of spliced to unspliced
form (s/u) is indicated below. The experiments were repeated three times and the representative results are shown.
doi:10.1371/journal.pone.0006868.g004
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PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6868Figure 5. Mutation in ATP binding domain of GRP78va attenuates eIF2a phosphorylation. A. Schematic representation of human GRP78,
GRP78va, and the ATP binding mutant GRP78va-G80D. The position of mutation site is indicated. B. Western blots to detect ectopic expression of
GRP78va and the mutant in stably transfected HeLa cell lines. The GRP78va proteins and endogenous canonical GRP78 were detected by the anti-HA
Cytosolic Form of GRP78/BiP
PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6868level (Figure 7B) was confirmed. Compared to control siRNA, cells
transfected with siGrp78va showed significant attenuation of eIF2a
phosphorylationinduced by Tg treatment (Figure 7C).Western blot
analyses further showed increased levels of the cleaved products of
caspase-3 and -7 in Tg-treated cells transfected with siGrp78va, as
compared to control siRNA (Figure 7D), corresponding with
decrease in cell survival as measuredby soft agar clonogenic assay in
cells where GRP78va was knocked down (Figure 7E). Similarly, in
colony survival assays, knockdown of GRP78va reduced viability of
Tg-treated HeLa cells (Figure S7A), whereas overexpression of
GRP78va enhanced cell survival (Figure S7B).
Discussion
Alternative splicing is a major mechanism for generating protein
diversity, expressing proteins that are related but with diverse
function and localization. Interestingly, a large number of
apoptotic regulators undergo alternative splicing, suggesting that
this is a crucial mechanism for survival and death decisions [24].
GRP78/BiP, which represents a major anti-apoptotic arm of the
UPR, has been traditionally regarded as an ER lumen chaperone
protein [4,16]. Recently, GRP78 has also been localized on the
cell surface [34,35]. Although the amount of surface GRP78
represents only a very small fraction of cellular GRP78, it has been
implicated in enhancing mitogenic signaling, proliferation and cell
survival [15,17,36–40]. Here, we report the discovery of
GRP78va, a novel cytosolic isoform of GRP78 generated by
alternative splicing of Grp78 nuclear pre-mRNA. Our findings
suggest the ability of GRP78va to mediate a previously
unanticipated positive feedback regulation of PERK, potentially
via cytosolic interaction with P58
IPK. Our studies reveal several
novel observations which may have important clinical implications
in leukemia and other pathophysiological conditions that express
this isoform.
and anti-GRP78 antibody respectively, with b-actin as loading control. C. Time course analysis of eIF2a phosphorylation in Tg-treated HeLa cells
stably expressing HA-GRP78va or the mutant. Western blots were performed to determine total and phospho-eIF2a levels (upper panel). The ratio of
phospho-eIF2a to total eIF2a from two independent experiments are summarized and expressed as the mean with the indicated standard deviation
(SD) (lower panel). P values for all time points are indicated. D. Time course analyses of Tg induction of Grp78va and canonical Grp78 transcripts by
RT-PCR. HL-60 cells were treated with Tg (300 nM) for the indicated time and the total RNA was subjected to RT-PCR (left panel). The experiments
were repeated three times. The results are summarized and expressed as the mean of the normalized Grp78va or canonical Grp78 levels with the
indicated SD (right panel). E. Time course analyses of Tg induction of canonical GRP78, GRP78va, P58
IPK and eIF2a phosphorylation (p-eIF2a). HL-60
cells treated with Tg (300 nM) for the indicated time were used for Western blot for detection of the indicated proteins with b-actin as loading control
(left panel). The experiments were repeated twice. The levels of canonical GRP78, GRP78va and P58
IPK normalized to b-actin and the ratio of phospho-
eIF2a to total eIF2a are summarized and plotted respectively (right panel).
doi:10.1371/journal.pone.0006868.g005
Figure 6. Physical and functional interactions between GRP78va and P58
IPK.A .Co-immunoprecipitation of GRP78va with P58
IPK. 293T cells
co-transfected with pcDNA/P58
IPK-FLAG (schematic drawing shown above) and pcDNA/HA-Grp78va were either non-treated (2) or treated with Tg
(300 nM) for 16 hours. Immunoprecipitations were performed with either anti-FLAG antibody or control mouse IgG, followed by Western blot with
the respective antibodies. The input levels are shown. B. Reduced binding between FLAG-P58
IPK and ATP binding mutant of GRP78va. 293T cells
were co-transfected with pcDNA/FLAG-P58
IPK and pcDNA/HA-Grp78va or the mutant Grp78va-G80D. Immunoprecipitations were performed with
anti-FLAG antibody or control IgG, followed by Western blot. C. Cytosolic localization of P58
IPK determined by the cell permeabilization assay. HeLa
cells transiently transfected with pcDNA/P58
IPK-FLAG were permeabilized by 0.01% digitonin for 5 minutes. The various fractions were subjected to
Western blots for the proteins as indicated. P58
IPK-FLAG(SS) designates P58
IPK with a slower electrophoretic mobility being released from the
permeabilized cells, consistent with retention of signal sequence. D. Overexpression of FLAG-P58
IPK suppressed eIF2a phosphorylation mediated by
GRP78va. Following transient transfection of the P58
IPK expression plasmid or vector into the indicated stably transfected HeLa cell lines, Western
blots were performed to probe for the indicated proteins. The experiments were repeated twice. The representative Western blots are shown with
the ratio (p/t) of phospho-eIF2a to total eIF2a indicated. E. Overexpression of GRP78va reduced endogenous P58
IPK levels. Western blots were
performed in HeLa cells stably transfected with vector or HA-GRP78va expression plasmid. The experiments were repeated three times. The
representative Western blots are shown and the P58
IPK levels normalized to b-actin are indicated below. F. Knockdown of GRP78va increased
endogenous P58
IPK level. Western blots were performed with HeLa cells transfected with control siRNA (siCtrl) or Grp78va siRNA (siGrp78va) to detect
endogenous P58
IPK and b-actin level. The cells were either non-treated (2) or treated (+) with Tg (300 nM) for 16 hours. The P58
IPK levels normalized
to b-actin are shown below the immunoblots. Statistical comparisons were made between Tg-treated cells transfected with siCtrl or siGrp78va,
p=0.03.
doi:10.1371/journal.pone.0006868.g006
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on the structure and function of GRP78/BiP over the past 25
years? Difficulty to detect the isoform proteins generated from
alternative spliced mRNAs could be due to transcript instability,
reduced translation efficiency or instability of the new proteins.
The abundance of Grp78va mRNA may be affected by nonsense-
mediated RNA decay (NMD). NMD is a quality-control
mechanism that selectively degrades mRNAs harboring premature
termination (nonsense) codons. Most recently, it was reported that
NMD is inhibited in ER-stressed cells and this inhibition is
dependent on eIF2a phosphorylation [41]. The repression of
NMD stabilizes the target mRNAs, including the UPR factors
ATF4, ATF3 and CHOP, and thereby arguments the cellular
stress response. With the introduction of a premature stop codon
by intron 1 retention, Grp78va mRNA is a potential NMD target.
Upon ER stress, inhibition of NMD could lead to stabilization of
Grp78va mRNA and translation of functional GRP78va protein.
Since GRP78va initiates by an internal AUG that is also contained
in the canonical GRP78 transcript, the issue arises whether
internal initiation might also occur. In our experimental design,
the siRNA against GRP78va specifically targets the retained
intron 1 of the Grp78va transcript, thereby affecting only
translation from the Grp78va transcript but not internal initiation
from the fully spliced, canonical Grp78 transcript. We observed
that the decrease in GRP78va protein level generally corresponds
with the decrease in the Grp78va transcript level in the siGrp78va-
treated cells (Figure S5), suggesting that the majority of GRP78va
results from Grp78va mRNA translation. At the post-translational
level, HA-GRP78va, was stabilized by the proteasome inhibitor
MG115, whereas endogenous GRP78 was not affected (Figure
S8A), consistent with a much shorter half life for GRP78va
compared to canonical GRP78, as determined by the cyclohex-
imide chase experiment (Figure S8B). Analysis of the protein
amino acid sequence revealed a potential PEST-rich region at the
carboxy-terminus of GRP78va (Figure S8C). PEST sequences are
present in regulatory proteins, such as transcription factors,
Figure 7. GRP78va protects HL-60 cells from ER stress-induced cell death. A, B. Knockdown of GRP78va in HL-60 cells. RT-PCR (A, left panel)
or quantitative real-time PCR (A, right panel) was used to determine the level of Grp78va transcript in HL-60 cells transfected with the indicated siRNA.
Western blot. B was performed to determine the levels of the proteins indicated. C. Inhibition of Tg-induced eIF2a phosphorylation by knockdown of
GRP78va. HL-60 cells were transfected with either siCtrl or siGrp78va. After treatment with Tg (300 nM) for the indicated time, phospho-eIF2a and
total eIF2a were detected by Western blot (upper panel). The experiments were repeated three times. The results are summarized and the ratio of p-
eIF2a/eIF2a is plotted with SD (lower panel). The ratio of the non-treated, siCtrl transfected cells was set as 1. P values are indicated. D. Western blot
of caspase-7, cleaved caspase-3 and b-actin in siRNA-transfected HL-60 cells treated with Tg for 24 hours. E. Soft-agar clonogenic survival assay for
HL-60 cells after transfection with the indicated siRNA for 72 hours and then treated with Tg (300 nM) for the indicated time.
doi:10.1371/journal.pone.0006868.g007
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carboxy-terminus in these proteins, serving as a proteolytic signal
contributing to rapid degradation of proteins [42,43]. While
canonical GRP78 also contains the same PEST sequence, the ER
compartment where it is localized likely protects it from
recognition and degradation by ubiquitin-proteasome system.
Here we report that with the proper PCR primers, the
alternatively spliced Grp78va transcript is readily detectable in
mouse embryos, specific adult tissues, as well as peripheral blood
and bone marrow samples from leukemic patients. The GRP78va
expression pattern matches well with predictions from the
genome-wide exon junction microarray [28] and is represented,
albeit rarely, in the current expressed sequence tag (EST) database
which tends to bias against less abundant alternative forms. While
GRP78va may have diverse cellular function which awaits future
investigation, here we establish that GRP78va exhibits anti-
apoptotic activity against ER stress.
How might GRP78va protect cells from ER stress induced cell
death? In contrast to canonical GRP78, GRP78va is cytosolic due
to the lack of the amino-terminal ER signal sequence. Based on
previous studies of GRP78 mutants, the GRP78va isoform
corresponds to the protein initiating at Met-148/153 which
showed greater ATP binding than the wild-type GRP78 [44].
Thus, the conservation of both the ATP binding and the peptide
binding domains in GRP78va suggests that it can act as a cytosolic
counterpart of canonical GRP78, interacting with client proteins
playing critical roles in cell survival. One key function of the ER
localized canonical GRP78 is its ability to regulate ER stress
signaling by maintaining ER transmembrane sensors PERK,
IRE1 and ATF6 in their inactive state in non-stressed cells. As a
first test of GRP78va function, we examined whether it affects ER
stress signaling pathways. Using both overexpression and knock-
down approaches, we discovered that GRP78va selectively
upregulates PERK signaling. Further, point mutation of GRP78va
defective in ATP binding greatly diminished its regulatory effect
on induction of eIF2a phosphorylation, suggesting that GRP78va
acts through its interaction with cytosolic client protein(s) capable
of modulating PERK activity.
Here we identified P58
IPK as the first client protein of
GRP78va. There are some discrepancies in literature regarding
the subcellular localization of P58
IPK, as its activity has been
documented in both the cytosolic and the ER compartments.
P58
IPK was originally discovered as a cytosolic protein but later
discovered to possess a weak ER signal peptide sequence
[20,23,30]. There are precedents in literature where an ER
protein can also localize in the cytosol. Potential mechanisms
include inefficient translocation due to weak signal peptide
sequence [45], retrotranslocation from the ER lumen to the
cytosol after peptide cleavage inside the ER [46]; after signal
peptide cleavage but prior to ER insertion, translocation can be
aborted and the product released into the cytosol [47]; and
retrotranslocation from the ER lumen to the cytosol via ERAD
but escapes proteasome degradation [48]. Further, different cell
lines exhibit wide variations in the extent of relocation [46].
Results from our studies in HeLa cells are consistent with
insufficient translocation of P58
IPK due to weak signal sequence
[23], and provide a plausible explanation for the original role of
P58
IPK as an inhibitor of the cytosolic kinase activities of PERK
and PKR [20,30], as a cytosolic component of the translocon [22],
and the recent finding that P58
IPK regulates influenza virus
mRNA translation and replication through a PKR-mediated
mechanism in the cytosol [49]. Further, as the minor cytosolic
population of P58
IPK is able to inhibit the low abundance PERK
or PKR kinase, this inhibition could be suppressed by low amount
GRP78va through antagonizing the cytosolic P58
IPK. In addition,
the distribution of P58
IPK between the ER and cytosol could be
different in different cell types, such as mouse embryonic
fibroblasts (MEFs) versus human cancer cells, or under different
cellular conditions, such as normal physiological versus patholog-
ical conditions. Future investigations will be required to resolve
how these factors contribute to P58
IPK subcellular localization and
function.
Our results also predict that other cytosolic co-chaperone
proteins might associate with GRP78va and assist its function. It is
known that Hsp70 proteins employ DnaJ family proteins as co-
chaperones, which preferentially bind to the ATP form of their
partner Hsp70 and stimulate the ATPase activity to stabilize
Hsp70-polypeptide complexes [50,51]. DnaJ/Hsp40 chaperone
proteins interact with the conserved ATPase domain of HSP70
proteins through their conserved J-domain. As the ER lumenal
HSP70 chaperone, GRP78 is known to interact with a group of
DnaJ/Hsp40 proteins in the ER lumen, such as ERdjs [52–54].
Since GRP78va retains most part of ATPase domain of canonical
GRP78, it is expected to potentially bind other cytosolic
chaperones, such as DnaJ/Hsp40 proteins besides P58
IPK. Further
experiments are necessary to characterize the cytosolic co-
chaperone proteins of GRP78va. It is also tempting to speculate
that GRP78va might act as a cytosolic chaperone collaborating
with its cytosolic co-chaperones to promote the folding of nascent
cytosolic polypeptides, since it corresponds to the GRP78 mutant
initiated from Met-148 in previous study and exhibits strong ATP
binding activity [44], implicating that GRP78va has the ability to
bind to client proteins.
Induction of GRP78 and activation of PERK signaling
represents two major pro-survival pathways in the UPR. GRP78
promotes ER protein folding and efficient degradation of
aggregated proteins through ERAD, which alleviates the unfolded
protein load in the ER and increases cell survival. Likewise,
PERK-mediated eIF2a phosphorylation is protective by attenu-
ating the protein biosynthesis and consequently reducing the total
protein load on the ER. Thus, both GRP78 upregulation and
PERK activation promote cell survival and adaptation to
pathophysiological stress [5,15,32,33,55,56]. P58
IPK is inducible
by ER stress. The cells employ the cytosolic population of P58
IPK
to inhibit PERK activity, allowing the cells to recover from global
translational inhibition. Our data suggests that ER stress also
induces GRP78va as a cytosolic counterpart of GRP78, and a
potential feedback mechanism to regulate P58
IPK. Through
complex formation with cytosolic P58
IPK, GRP78va may act as
an antagonist of P58
IPK. Thus, when GRP78va is overexpressed,
the level of P58
IPK was decreased and PERK signaling was
enhanced. Therefore, GRP78va has the ability to function as a
novel regulator of PERK signaling under ER stress and this
regulation may play an important role especially in cancer cells
where GRP78va is highly expressed. However, since sustained
PERK activation could be harmful [57] and persistent ER stress
attenuates survival pathways mediated by IRE1 and ATF6
signaling [19], this may explain why GRP78va expression might
be stringently regulated at the transcript stability level, as well as at
the post-translational level.
Aberrant splicing has been found to be associated with various
diseases, including cancer [25]. In this study, through microarray
and biochemical analysis, we discovered that leukemic cell lines
and leukemia patients expressed high levels of GRP78va. Evidence
suggests that alteration of phosphorylation and/or expression of
proteins that recognize splice sites and assembly of the splicesome
in leukemia can be caused by aberrant BCR/ABL fusion protein,
deregulated expression of DNA topoisomerase I or the hemato-
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incidence of intron retention of Grp78 in leukemic patients may be
due to alteration of the pre-mRNA splicing machinery. On the
other hand, genomic mutations associated with oncogenesis may
also interfere with the recognition and selection of splice sites and
affect pre-mRNA splicing pattern.
Considering the high expression of GRP78va in leukemia and
its pro-survival role against ER stress, how might leukemic cells
experience ER stress? Recent reports suggest that retroviral
infection, the pathologically expressed fusion protein PML-RARa
and reactive oxygen species can induce ER stress in leukemic cells
[60,61]. Therapeutic drugs in clinical treatment or pre-clinical
test, such as arsenic trioxide and imatinib mesylate, have been
shown to upregulate ER stress markers and induce leukemic cell
death through ER stress-mediated apoptosis [62]. Further,
proteomic analysis discovered that GRP78 is differentially
expressed in the hematopoietic stem cell (HSC)-like fractions from
the bone marrow of leukemia patients [63]. It will be interesting to
determine if GRP78va is also elevated in parallel with GRP78 in
the HSC cell fractions. While GRP78 is established to be critical
for solid tumor progression and drug resistance [5,15,55,64–69],
the role of GRP78 and GRP78va in hematological cancers
remains to be determined. The discovery of the novel cytosolic
isoform GRP78va points to a new paradigm for how GRP78
functions in regulating cell homeostasis and future identification of
other client proteins of GRP78va will yield new insight on how
GRP78 and UPR signaling regulate cell survival and death
beyond the ER compartment.
Materials and Methods
Cell culture
Human cell lines HeLa, MDA-MB-435, HCT116, A549, MCF-
7, HBL100, 293T and mouse fibroblast NIH3T3 cells were
cultured in Dulbecco’s modified Eagle medium (DMEM)
containing 10% fetal bovine serum and 1% penicillin/streptomy-
cin. Human lymphoma cell line Raji, APL cell line HL-60 and
CML cell line K562 were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum and 1% penicillin/
streptomycin.
RT-PCR and quantitative real-time PCR
Total RNA from cell cultures, mouse embryos and tissues was
extracted by Trizol reagent (Invitrogen) and treated with DNase I
before converted to cDNA by using SuperScript II reverse
transcriptase (Invitrogen) with oligo d(T) primer following the
manufacturer’s instruction. For quantitative real-time PCR, cDNA
samples from human cell lines were analyzed in triplicate with the
SYBRH Green Supermix (BioRad) using iCycler Real-Time PCR
Detection System (BioRad). All primer sets were tested for PCR
efficiency as recommended by the manufacturer’s instruction. A
standard curve was prepared for each set of primers using serial
titration of the cDNA samples. The relative mRNA level was
calculated from primer-specific standard curves using the iCycler
Data Analysis Software and normalized to GAPDH levels. Specific
PCR primers for Grp78 or Grp78va are indicated in Figure 1A and
the sequence of primers are listed in the Supporting Information
S1.
cDNA cloning and plasmid construction
Bridging-based two round PCR was used to amplify human
Grp78va cDNA sequence and the cloning procedure for the
construction of all the expression plasmids were described in the
Supporting Information S1. All the clones were verified by
sequencing.
Clinical specimens
Leukemic blasts from bone marrow and peripheral blood
samples were generously provided by Dr. Allen Yang (University
of Southern California Keck School of Medicine). They were
obtained from diagnosed leukemia patients in USC/Norris
Comprehensive Cancer Center according to institutional guide-
lines. The ethical use of the human tissues for research was
approved by the University of Southern California Institutional
Review Board. Written consent was obtained.
In vitro transcription and translation assay
One mg of the template plasmid DNA was applied in the TNTH
quick coupled transcription/translation assay (Promega) following
the manufacturer’s protocol.
Transfection methods
For transfection of plasmids, Polyfect reagent (Qiagen) was used
following the manufacturer’s protocol. The stable cell lines were
established by transfecting the expression plasmids into HeLa cells,
followed by selection with G418 (400 mg/ml, Gibco) for 2 weeks.
Individual clones were picked, trypsinized and seeded to 24 well-
plate for further culture in fresh DMEM medium supplemented
with G418 (200 mg/ml). For transfection of siRNA, Lipofectami-
ne
TM 2000 reagent (Invitrogen) was used following manufacturer’s
protocol. The sequence of siRNA against Grp78va and control
siRNA were described in the Supporting Information S1.
Preparation of post-nuclear lysate
Cells were resuspended in ice cold NE buffer A (10 mM Hepes,
pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 10 mM EDTA, 0.35% NP-
40, 1x protease inhibitor complex), rotated at 4uC for 10 minutes
and centrifuged to collect the supernatant as the PN fraction,
which were stored in 280uC for further analysis.
Cell permeabilization
Digitonin was used to selectively permeabilize the plasma
membrane of cells but not the organelle membrane, as previously
described [46]. Briefly, about 10
6 HeLa cells were transfected with
the indicated expression vectors. After 48 hours, the cells were
trypsinized and collected by centrifugation. Half of the cells were
lysed in 500 ml of RIPA buffer supplemented with competent
protease-inhibitor cocktail (Roche), and the other half were
resuspended in 500 ml of transport buffer (20 mM HEPES,
pH 7.4, 110 mM potassium acetate, 2 mM magnesium acetate,
0.5 mM EGTA) supplemented with proteinase inhibitor cocktail.
Cell permeabilization was carried out in 0.01% digitonin for 5
minutes on ice. The supernatant and pellet were collected by
centrifugation. The cell pellet was resuspended in 500 ml of RIPA
buffer. Equivalent volumes of intact cells, permeabilized cells, and
the released fraction were analyzed by Western blot.
Western blot analysis
Cells were lysed in RIPA buffer supplemented with competent
protease-inhibitor mixture (Roche) and 50 mg cell lysate was
subjected to SDS-PAGE. The immunoblot membranes were
probed with primary antibody and the protein signals were
detected with the ECL reagent (Roche) or Supersignal chemilu-
minescence reagent (PIERCE) after reacting with HRP-conjugat-
ed secondary antibody. The source and dilution of the primary
antibodies were listed below.
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anti-PERK (1:1000), rabbit anti-ATF4 (1:1000), monoclonal
mouse anti-CHOP (1:2000) and rabbit anti-ATF6 (1:1000) are
from Santa Cruz Biotechnology. Rabbit anti-phospho-PERK
(1:1000), rabbit anti-p-eIF2a (1:1000), rabbit anti-eIF2a (1:1000)
and rabbit anti-cleaved caspase-3 (1:2000) are from Cell Signaling
Biotechnology. Monoclonal mouse anti-b-actin (1:5000) and
monoclonal mouse anti-FLAG (1:5000) are from Sigma. Mono-
clonal mouse anti-GRP78 (1:2000, Cat. No. 610978) and
monoclonal mouse anti-caspase-7 antibody (1:4000) are from
BD Pharmingen. Monoclonal mouse anti-P58
IPK is a gift from
M.G. Katze (University of Washington).
Confocal immunofluorescence microscopy
The cells were fixed with 4% paraformaldehyde at room
temperature for 10 minutes and washed twice with PBS.
Immunofluorescence staining was performed as previously de-
scribed [70]. The primary antibodies used are anti-HA polyclonal
antibody and anti-GRP78 (H-129) antibody (1:500, Santa Cruz
Biotechnology), followed by FITC-conjugated secondary antibod-
ies (Vector Labs). The cells were mounted in Vectashield
mounting medium (Vector Labs) and visualized on a Perkin-
Elmer/Zeiss confocal microscope.
Co-immunoprecipitation assay
The protocol for co-immunoprecipitation with the anti-FLAG
antibody has been described [14].
Soft agar colongenic survival assay
A 0.3% soft agar solution was prepared by adding one volume of
autoclaved1.5% lowmelting temperature agarose tofour volume of
RPMI 1640 medium. HL-60 cells were mixed with the soft agar
solution at a density of 300 cells/well in 6-well plates. The plating
was performed in triplicate. Ten days later, the colonies with more
than 50 cells were counted under inverted microscope. The survival
fraction was normalized by dividing the number of surviving
colonies of treated groups by that of untreated control groups.
Supporting Information
Supporting Information S1 Supporting information and
figure legends
Found at: doi:10.1371/journal.pone.0006868.s001 (0.05 MB
DOC)
Figure S1 Discovery of the Alternative Transcript of Grp78. (A)
Schematic representation of the intron 1 splicing in mouse Grp78.
Arrows labeled as p1 and p2a indicate the primers used in RT-
PCR. (B) RT-PCR was performed with cDNA samples from Tg-
treated or non-treated NIH3T3 cells by using the primer set
p1p2a. To assess the genomic contamination, PCR with the total
RNA samples used for reverse transcription was performed. The
gel image is shown with inverted background. (C) Alignment of the
intron 1 sequence of human and mouse Grp78va. Arrows indicate
the suboptimal splicing sites in human and mouse Grp78va. (D)
Alignment of the primer p2a flanking sequence and the junction
sequence of intron 1 and exon2 in mouse Grp78.
Found at: doi:10.1371/journal.pone.0006868.s002 (0.50 MB TIF)
Figure S2 Induction of Grp78va Transcript by Tunicamycin
and L-azetidine 2-carboxylic Acid. HeLa cells were either non-
treated (2) or treated with 1.5 ug/ml tunicamycin (Tun) or 5 mM
L-azetidine 2-carboxylic acid (AzC) for 16 h. Total RNA was
subjected to RT-PCR with the specific primers (p1/3 and p4/5)
for the human homologue of mGrp78va shown in Figure 1A. b-
actin levels served as control.
Found at: doi:10.1371/journal.pone.0006868.s003 (0.18 MB TIF)
Figure S3 Bioinformatic Analysis of Intron 1 Retention
Alternative Splicing of Human Grp78 by Using a Microarray
Database. Analysis of the microarray data was described in the
Supporting Information Materials and Methods. The values of X-
axis show the difference between the intensities of exon 1/2 and
exon 2/3 probes in each tissue sample and the numbers plotted
vertically correspond to human tissues or cancer cell lines included
in the microarray database.
Found at: doi:10.1371/journal.pone.0006868.s004 (0.65 MB TIF)
Figure S4 Detection of GRP78 but not GRP78va by an Anti-N
Terminus GRP78 Antibody. HeLa cells were transiently trans-
fected with pcDNA3 (lane 1) or pcDNA/GRP78va-sm (lane 2) for
48 h. The cell lysates were analyzed by Western blots. Left panel
shows immunoblot with anti-N-terminus GRP78 antibody (N-20
from Santa Cruz Biotechnology); right panel shows immunoblot
with anti-C-terminus GRP78 antibody (C 20 from Santa Cruz
Biotechnology). In the left panel, the asterisk (*) denotes a non-
specific protein band that immunoreacts with the N-20 antibody.
Found at: doi:10.1371/journal.pone.0006868.s005 (0.23 MB TIF)
Figure S5 GRP78va is the Protein Product of the Grp78va
Transcript. (A) Schematic diagram of Grp78va and canonical
Grp78 mRNA showing the target (red arrow) of Grp78va-specific
siRNA (siGrp78va) in intron 1 retained in Grp78va mRNA. (B)
HeLa cells were transfected with siCtrl or siGrp78va for 72 h. The
Grp78va and total Grp78 mRNA levels were evaluated by
quantitative real-time PCR. The results were summarized and
plotted with standard deviations. (C) HeLa cells were transfected
with siCtrl or siGrp78va for 72 h. Endogenous GRP78va and
canonical GRP78 were detected by Western blots using anti-
GRP78 monoclonal antibody with b-actin as loading control. For
the abundant canonical GRP78, a light exposure is shown. (D)
The experiments described in (C) were repeated three times. The
GRP78va and GRP78 protein levels were quantitated and
normalized to b-actin level. The results were summarized and
plotted with standard deviations.
Found at: doi:10.1371/journal.pone.0006868.s006 (0.53 MB TIF)
Figure S6 Dual Localization of P58IPK in the ER and the
Cytosol. HeLa cells transiently transfected with pcDNA/P58IPK-
FLAG were fixed in methanol and stained with anti-FLAG
monoclonal antibody (1:1000, Sigma) for detection of P58IPK
(red), followed by anti-PDI polyclonal antibody (1:500, Santa Cruz
Biotechnology)astheERmarker(green),and then DAPItoindicate
the nucleus (blue). The cells were subjected to confocal microscopy.
The individual images and the merged image are shown.
Found at: doi:10.1371/journal.pone.0006868.s007 (2.10 MB TIF)
Figure S7 GRP78va Promotes HeLa Cell Survival During ER
Stress. (A) HeLa cells transfected with siCtrl or siGrp78va were
exposed to Tg (1 uM) for the indicated hours and then re-plated in
fresh medium for colongenic survival assay (see Supporting
Information Materials and Methods). After 10–14 days, the
colonies were counted and the survival fractions were plotted
against the time of treatment as indicated. (B) HeLa cells stably
overexpressing GRP78va (Grp78va) or control cells (vector) were
treated with Tg (1 uM) for the indicated hours and then subjected
to colongenic survival assay.
Found at: doi:10.1371/journal.pone.0006868.s008 (0.32 MB TIF)
Figure S8 GRP78va is Stabilized by Proteasome Inhibitor (A)
Proteasome inhibitor stabilizes overexpressed HA-GRP78va.
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either non-treated (2) or treated (+) with MG115 (2 h) or Tg
(16 h) as indicated and subjected to Western blots. The HA-
GRP78va levels normalized to b-actin are indicated below. (B)
GRP78va has a short half-life. 293T cells were transfected with
pcDNA/HA-GRP78va and after 24 h, the cells were seeded onto
the 6-well plates. Next day, the cells were treated with
cycloheximide (CHX) for the time (in hours) indicated on top.
The cell lysates were collected and analyzed by Western blot using
antibodies against GRP78 (C-20) and b-actin. The positions of
GRP78 and HA-GRP78va are indicated. The HA-GRP78va
levels normalized to b-actin are indicated below. (C) Alignment of
human and mouse GRP78va with human GRP78 protein
sequence. The mouse GRP78va amino acids divergent from
human GRP78 and GRP78va are highlighted in red. The PEST-
rich region is boxed, and the enrichment of proline (P), glutamic
acid (E), serine (S), and threonine (T) residues are bolded.
Found at: doi:10.1371/journal.pone.0006868.s009 (0.67 MB TIF)
Table S1 Summary of alternative splicing by intron retention
from Grp78va gene.
Found at: doi:10.1371/journal.pone.0006868.s010 (0.53 MB TIF)
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